Table 1 Characteristics at diagnosis and follow-up for patients (N = 279), split by treatment group. Median values and range are reported for the groups
From: Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome
| CBCT+a MetS+b | CBCT− MetS+ | CBCT+ MetS− | CBCT− MetS− | CBCT model p value | MetS model p value | |
|---|---|---|---|---|---|---|
| N | 61 | 34 (32c) | 115 | 69 | ||
| Age at diagnosis (years) | 30 (18–52) | 30 (16–49) | 27 (16–47) | 28 (18–52) | 0.09 | < 0.001 |
| Age at sample collection (years) | 48 (29–64) | 45 (28–74) | 44 (23–61) | 43 (26–62) | 0.81 | < 0.001 |
| Age at survey II (years) | 51 (36–69) | 52 (36–68) | 47 (31–66) | 48 (33–68) | 0.06 | < 0.001 |
| Time between surgery and sample collection (years) | 17 (5–27) | 18 (6–35) | 17 (6–28) | 14 (5–28) | 0.02 | 0.02 |
| Time between sample collection and MetS diagnosis (years) | 0 (0–9) | 8 (− 8–9) | 0 (0–9) | 8 (0–9) | <0.001 | 0.09 |
| Clinical characteristics at diagnosis | ||||||
| Initial disease stage | < 0.001 | 0.58 | ||||
| I | 18 | 32 | 35 | 66 | ||
| IMK positived/II | 36 | 0 | 58 | 3e | ||
| III | 2 | 0 | 4 | 0 | ||
| IV | 5 | 0 | 18 | 0 | ||
| Histology | 0.16 | 0.15 | ||||
| Seminoma | 8 | 1 | 6 | 2 | ||
| Non-seminoma | 53 | 31 | 109 | 67 | ||
| Cumulative cisplatin dose (mg) | 790 (570–920) | 760 (495–1400) | < 0.001 | |||
| Selected characteristics at follow-up | ||||||
| Testosterone (nmol/L)f | 11.1 (3–26) | 12 (3–24) | 15 (3–32) | 16 (6–38) | 0.30 | < 0.001 |
| Physical activity | 0.40 | 0.002 | ||||
| Very active | 26 | 12 | 72 | 36 | ||
| Moderate | 25 | 16 | 37 | 28 | ||
| Sedentary | 10 | 4 | 5 | 4 | ||
| Smoking status | 0.77 | 0.13 | ||||
| Never smoker (%) | 43 | 33 | 51 | 49 | ||
| Former smoker (%) | 34 | 42 | 24 | 28 | ||
| Current smoker (%) | 23 | 24 | 24 | 23 | ||
| Mean β methylation | 0.62 | 0.62 | 0.62 | 0.62 | 0.21 | 0.71 |
